ALVR AlloVir, Inc.
AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John Wilson, and Ann M. Leen in 2013 and is headquartered in Houston, TX.
$30.99 -3.54 (-10.25%)
As of 03/05/2021 14:12:11 EST IEX book CBOE book
Security Information
Category2:
Category3:
GICS sector:
Industry:
Index country:
Country of incorporation:
IPO date:
Outstanding shares:
Average volume:
Market cap:
Current dividend yield:
All SEC filings:
Quarterly filings:
Annual filings:
CUSIP:
ISIN:
Sedol:
Common stocks
Mid cap
Health Care
Biotechnology
USA
USA
07/30/2020
65,106,873
246,506
$2,248,140,325
0.00%
SEC Edgar Online
10-Q
10-K
019818103
US0198181036
BL9XBL4
Valuation (See tab for details)
PB ratio:
PS ratio:
Return on equity:
Net income %:
6.37
0.00
-19.77%
0.00%